March 31, 2021 March 31, 2021Categories Active Clinical TrialsTrial Spotlight: Amer Zeidan on the BLAST MRD CML 1 Study for Chronic Myeloid LeukemiaThe EA9171 phase II trial aims to determine if adding pembrolizumab immunotherapy to standard-of-care TKI therapy helps more patients achieve undetectable minimal residual disease and allows them to discontinue TKI therapy
December 14, 2020 December 14, 2020Categories Active Clinical TrialsNow Enrolling: ECOG-ACRIN Opened Five New Trials in OctoberThe five phase III trials span different cancer types: prostate, leukemia, anal, lung, and myeloma
January 14, 2020 January 14, 2020Categories Institution SpotlightsInstitution Spotlight: Fox Chase Cancer CenterA Standing Main Member of ECOG-ACRIN since 1971